Table 3.

Grade 3 or 4 adverse events (safety population)

Treatment-emergent	No	Eltrombopag	Eltrombopag	Eltrombopag
	Eltrombopag	75 mg	100 mg	150 mg
	(n = 3)a	(n = 7)	(n = 4)	(n = 1)
Hematologic AEs, n (%)
Thrombocytopenia	0	3 (43)	2 (50)	1 (100)
Neutropenia	2 (67)	4 (57)	4 (100)	0
Anemia	0	3 (43)	2 (50)	0
Leukopenia	0	3 (43)	0	0
Febrile neutropenia	0	2 (29)	0	0
Nonhematologic AEs, n (%)
Pulmonary embolism	1 (33)	0	0	0
Abdominal abscess	1 (33)	0	0	0
Abdominal pain	0	1 (14)	0	0
Mucosal inflammation	0	1 (14)	0	0
Dehydration	0	1 (14)	0	0
Subclavian vein thrombosis	0	1 (14)	0	0
Sepsis	0	0	1 (25)	0

^aPatients were withdrawn prior to receiving eltrombopag during the second cycle.

AE, adverse events.